These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 18612199)

  • 41. Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente.
    Rutkowski M; Mann W; Derose S; Selevan D; Pascual N; Diesto J; Crooks P
    Am J Kidney Dis; 2009 Mar; 53(3 Suppl 3):S86-99. PubMed ID: 19231766
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lipid changes and statins in chronic renal insufficiency.
    Ritz E; Wanner C
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S226-30. PubMed ID: 17130266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New insights into lipid metabolism in chronic kidney disease: what are the practical implications?
    Kaysen GA
    Blood Purif; 2009; 27(1):86-91. PubMed ID: 19169024
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of coronary artery disease in patients with chronic kidney disease.
    Coats WC; Baig SZ; Alpert MA; Aggarwal K
    Adv Perit Dial; 2009; 25():125-8. PubMed ID: 19886333
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs.
    Nogueira J; Weir M
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):766-85. PubMed ID: 17699494
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention of cardiovascular disease in chronic kidney disease patients.
    Wanner C
    Semin Nephrol; 2009 Jan; 29(1):24-9. PubMed ID: 19121471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Achieving chronic kidney disease treatment targets in renal transplant recipients: results from a cross-sectional study in Spain.
    Marcén R; del Castillo D; Capdevila L; Fernandez-Fresnedo G; Rodrigo E; Cantarell C; Fernández-Rodriguez A; López-Oliva MO; Camps J; Aljama P; Ortuño J; Arias M
    Transplantation; 2009 May; 87(9):1340-6. PubMed ID: 19424034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.
    Khurana M; Silverstein DM
    Pediatr Nephrol; 2015 Dec; 30(12):2073-84. PubMed ID: 25801207
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Dyslipidemia and stroke in patients with chronic kidney disease].
    Kes P; Bašić-Kes V; Furic-Cunko V; Mesar I; Bašić-Jukić N
    Acta Med Croatica; 2014 Apr; 68(2):141-9. PubMed ID: 26012152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [A risk factors for stroke in the patients with chronic kidney disease].
    Kes P; Basić-Kes V; Basić-Jukić N; Jurić I
    Acta Med Croatica; 2011 Oct; 65 Suppl 3():67-77. PubMed ID: 23120820
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Chronic kidney disease and atherosclerosis].
    Koike M; Nitta K
    Nihon Rinsho; 2011 Jan; 69(1):144-50. PubMed ID: 21226275
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quality of life in patients with chronic kidney disease: focus on end-stage renal disease treated with hemodialysis.
    Kimmel PL; Patel SS
    Semin Nephrol; 2006 Jan; 26(1):68-79. PubMed ID: 16412831
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular disease in children with chronic renal failure.
    Flynn JT
    Growth Horm IGF Res; 2006 Jul; 16 Suppl A():S84-90. PubMed ID: 16698298
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Chronic kidney disease and statins].
    Matovinović MS
    Lijec Vjesn; 2006; 128(11-12):345-50. PubMed ID: 17212196
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Underuse of American College of Cardiology/American Heart Association Guidelines in hemodialysis patients.
    Gowdak LH; Arantes RL; de Paula FJ; Krieger EM; De Lima JJ
    Ren Fail; 2007; 29(5):559-65. PubMed ID: 17654318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lipids and renal disease.
    Trevisan R; Dodesini AR; Lepore G
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S145-7. PubMed ID: 16565240
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Dyslipidemias in renal diseases: pathogenesis and treatment].
    Cuevas A; Maíz A; Arteaga A
    Rev Med Chil; 1998 Mar; 126(3):315-21. PubMed ID: 9674303
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
    Romayne Kurukulasuriya L; Athappan G; Saab G; Whaley Connell A; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):49-59. PubMed ID: 19124395
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
    Heinz J; Kropf S; Luley C; Dierkes J
    Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Renal dyslipidemia in patients on chronic hemodialysis].
    Kovacić V; Sain M; Vukman V
    Lijec Vjesn; 2003; 125(3-4):77-80. PubMed ID: 12899098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.